Nam In-soon's drug price recovery bill excludes rebates

It includes re-evaluation of original patent expiration and registration contracts. Kim Won is different from the bill

Upper limit of loss amount, 40% limit of difference

The "Return and refund of suspension of execution of drug prices" bill proposed by Rep.

 

Nam In-soon of the Democratic Party of Korea varies in scope of application to benefits deletion, suspension of benefits, and drug price reduction due to revaluation of starting drugs.

 

However, Rep.

 

Nam In-soon's bill does not include the disposition of drug price reduction due to the detection of illegal rebates.

 

The two bills differ in that the previously proposed Democratic Party lawmaker Kim Won-yi's bill was subject to redemption and refund of only the original patent expiration drug price and the rebate detection drug price.

 

As Rep.

 

Nam recently proposed an additional revision to the National Health Insurance Act, pharmaceutical companies that have conventionally applied for suspension of execution shortly after the patent expiration drug price was lowered have become more interested in the bill.

 

The National Assembly's Health and Welfare Committee announced the subcommittee on the first bill on the 23rd and 24th.

 

Therefore, it is not yet known whether the bill proposed by the two lawmakers will be reviewed by the end of this year.

 

Rep.

 

Nam's bill laid the groundwork for ex officio adjustment of the benefits, scope of benefits, and upper limit of registration drugs, as set by the Minister of Health and Welfare by Ordinance of the MOHW.(New Article 41-35) In particular, regarding the ex officio adjustment of the Minister of Health and Welfare, the NHIS specified the basis for collecting or refunding losses incurred by pharmaceutical companies filing administrative trials and administrative litigation.(New Article 101-2(1)-6) The ex officio adjustment of the Minister of Health and Welfare includes the expiration of the original patent, the registration of generics, and the deletion of benefits, suspension of benefits, and drug prices due to revaluation of registered drugs.

 

The disposition of drug prices for drugs caught in rebates was excluded.

 

This part is different from Kim Won-yi''s bill.

 

In the case of exclusion or suspension of benefits, the upper limit of losses cannot exceed 40/100 of the difference in medical care benefits.

 

The supplementary provisions stipulate the enforcement date of the bill as the day six months have elapsed since its promulgation.

 

The revised regulations were to be applied from administrative trials or administrative litigation filed for the first time since the enforcement of the law, so that past lawsuits for drug price reduction were not retroactively applied.